MUNICH – Results from a worldwide registry with more than 26,000 atrial fibrillation patients showed better survival with a direct oral...
Oral anticoagulation threshold according to CHA2DS2-VASc score varied widely after accounting for varying stroke rates in published studies.
The new guidelines highlight 60 key recommendations from the 12-person expert panel.
PARIS – Swedish registry report analyzes key clinical outcomes in more than 36,000 consecutive acute MI patients who received newer-generation...
MALMO, SWEDEN – Recognition of key risk factors warrants early screening ultrasound.
The obesity paradox makes a showing in the risk of all-cause death.
A reanalysis of the ATLAS ACS 2-TIMI 51 trial separated fatal and nonfatal events.
PARIS – “Given the high bleeding risk, single antiplatelet therapy seems to be a good option for these patients,” said Dr. Ulf Landmesser.
WASHINGTON – The preferred evaluation – intravascular ultrasound – was not used.
Andexanet alfa approval puts factor Xa inhibitors in the same ballpark as dabigatran, reversible with idarucizumab.
SAN DIEGO – Consider increased monitoring of renal function in certain patients.
We’ve come a long way in clinical trial representation of women, but there’s more work to do.
More than one-third of patients with an MI before age 50 and an LDL cholesterol of at least 160 mg/dL meet criteria for FH.
ORLANDO – Idarucizumab, reversal agent for the anticoagulant dabigatran, worked fine in patients with renal dysfunction.
SEATTLE – Thromboelastometry can play a role in identifying bariatric surgery patients at risk for VTE.
ECG patches may provide an inexpensive and noninvasive way to screen for asymptomatic atrial fibrillation in high-risk people.
The results “imply that there is a significantly unmet need for effective VTE prophylaxis in both the inpatient and outpatient continuum of care...
ORLANDO – “I believe this trial is going to change practice.” – Valentin Fuster, MD
ORLANDO – Mortality and major adverse cardiovascular events were cut 15%, but that’s not all.
